Capricor Therapeutics, Inc.
CAPR
$26.01
-$0.15-0.57%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -52.08% | -50.68% | -35.92% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -52.08% | -50.68% | -35.92% |
| Cost of Revenue | 60.80% | 69.02% | 67.30% | 54.51% | 44.87% |
| Gross Profit | -129.88% | -204.91% | -192.63% | -228.41% | -216.04% |
| SG&A Expenses | 60.23% | 59.35% | 56.43% | 43.40% | 26.11% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 60.67% | 66.80% | 64.73% | 51.87% | 40.16% |
| Operating Income | -109.38% | -154.07% | -139.80% | -144.67% | -118.97% |
| Income Before Tax | -108.11% | -159.58% | -140.34% | -150.39% | -126.47% |
| Income Tax Expenses | 0.00% | 0.00% | -- | -- | -- |
| Earnings from Continuing Operations | -108.11% | -159.58% | -140.35% | -150.39% | -126.48% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -108.11% | -159.58% | -140.35% | -150.39% | -126.48% |
| EBIT | -109.38% | -154.07% | -139.80% | -144.67% | -118.97% |
| EBITDA | -111.39% | -158.28% | -144.09% | -149.84% | -123.22% |
| EPS Basic | -62.97% | -88.48% | -69.35% | -76.39% | -62.09% |
| Normalized Basic EPS | -63.53% | -88.60% | -68.79% | -75.81% | -61.50% |
| EPS Diluted | -62.97% | -88.48% | -69.35% | -76.39% | -62.09% |
| Normalized Diluted EPS | -63.53% | -88.60% | -68.79% | -75.81% | -61.50% |
| Average Basic Shares Outstanding | 27.49% | 32.04% | 43.02% | 41.17% | 37.03% |
| Average Diluted Shares Outstanding | 27.49% | 32.04% | 43.02% | 41.17% | 37.03% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |